Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management
El efecto de este pptido sobre la densidad drmica y la morfologa de la superficie lo posiciona como un compuesto de referencia en formulaciones de investigacin cosmtica y dermatolgica
That event is tied to the DAC version , which keeps GH levels elevated for days
Outcome 2: Delayed drinking There are also lab experiments
Xue B et al
doi: 10.1371/journal.ppat.1000383
/assets/images/provider/photos/2714075.png)
US$ 22.28
US$ 28.10
US$ 20.10
US$ 26.08
US$ 20.21
US$ 23.34
